Skip to main content
NCBI home page
Gut logoLink to Gut
. 1985 Feb;26(2):114–119. doi: 10.1136/gut.26.2.114

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.

J Neuberger, E Christensen, B Portmann, J Caballeria, J Rodes, L Ranek, N Tygstrup, R Williams
PMCID: PMC1432420  PMID: 3881323

Abstract

One hundred and eighty nine patients with primary biliary cirrhosis were entered into a double blind, placebo controlled randomised trial starting in January 1978 to assess the therapeutic value of d-penicillamine 1200 mg daily. Eighteen of the 98 patients receiving d-penicillamine and 22 of the 91 placebo treated patients died during the study. Thirty six per cent of those on d-penicillamine and 8% of those on placebo were withdrawn from the study. No difference in overall survival was noted between the two groups of patients whether the results were analysed for the entire period of observation or only during the period in which the patients were receiving therapy. The mortality rate of those receiving d-penicillamine in histological stage I to II, however, was one third of that of the placebo group although this difference did not reach statistical significance. Using the occurrence rate ratio as the statistical method of analysis, no effect of d-penicillamine was noted on any clinical, biochemical or histological features examined, except the serum alanine aminotransferase activity which was greater in those on active treatment. In this trial we have been unable to establish any therapeutic benefit from the drug.

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandt L., Svensson B. Letter: Effect of penicillamine on peripheral-blood lymphocytes in rheumatoid arthritis. Lancet. 1975 Feb 15;1(7903):394–395. doi: 10.1016/s0140-6736(75)91309-4. [DOI] [PubMed] [Google Scholar]
  2. CARMAN C. T., GIANSIRACUSA J. E. Effect of steroid therapy on the clinical and laboratory features of primary biliary cirrhosis. Gastroenterology. 1955 Feb;28(2):193-207; discussion, 208-15. [PubMed] [Google Scholar]
  3. Crowe J., Christensen E., Smith M., Cochrane M., Ranek L., Watkinson G., Doniach D., Popper H., Tygstrup N., Williams R. Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology. 1980 May;78(5 Pt 1):1005–1010. [PubMed] [Google Scholar]
  4. Deshmukh K., Nimni M. E. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. II. Functional groups involved in the interaction process. J Biol Chem. 1969 Apr 10;244(7):1787–1795. [PubMed] [Google Scholar]
  5. Epstein O., Arborgh B., Sagiv M., Wroblewski R., Scheuer P. J., Sherlock S. Is copper hepatotoxic in primary biliary cirrhosis? J Clin Pathol. 1981 Oct;34(10):1071–1075. doi: 10.1136/jcp.34.10.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Epstein O., De Villiers D., Jain S., Potter B. J., Thomas H. C., Sherlock S. Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N Engl J Med. 1979 Feb 8;300(6):274–278. doi: 10.1056/NEJM197902083000602. [DOI] [PubMed] [Google Scholar]
  7. Epstein O., Jain S., Lee R. G., Cook D. G., Boss A. M., Scheuer P. J., Sherlock S. D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet. 1981 Jun 13;1(8233):1275–1277. doi: 10.1016/s0140-6736(81)92456-9. [DOI] [PubMed] [Google Scholar]
  8. Goldberg M. J., Kaplan M. M., Mitamura T., Anderson C. L., Matloff D. S., Pinn V. W., Agnello V. Evidence against an immune complex pathogenesis of primary biliary cirrhosis. Gastroenterology. 1982 Sep;83(3):677–683. [PubMed] [Google Scholar]
  9. Howat H. T., Ralston A. J., Varley H., Wilson J. A. The late results of long-term treatment of primary biliary cirrhosis by corticosteroids. Rev Int Hepatol. 1966;16(2):227–238. [PubMed] [Google Scholar]
  10. Jain S., Scheuer P. J., Samourian S., McGee J. O. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet. 1977 Apr 16;1(8016):831–834. doi: 10.1016/s0140-6736(77)92778-7. [DOI] [PubMed] [Google Scholar]
  11. Matloff D. S., Alpert E., Resnick R. H., Kaplan M. M. A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl J Med. 1982 Feb 11;306(6):319–326. doi: 10.1056/NEJM198202113060602. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Roll J., Boyer J. L., Barry D., Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983 Jan 6;308(1):1–7. doi: 10.1056/NEJM198301063080101. [DOI] [PubMed] [Google Scholar]
  14. Shapiro J. M., Smith H., Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut. 1979 Feb;20(2):137–140. doi: 10.1136/gut.20.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES